ESPN 50th Annual Meeting

ESPN 2017


 
EUROPEAN SURVEY ON DIAGNOSIS AND MANAGEMENT OF CRESCENTIC GLOMERULONEPHRITIS IN CHILDREN
ESRA BASKIN 1 REZAN TOPALOGLU 2

1- BASKENT UNIVERSITY
2- HACETTEPE UNIVERSITY
3- On behalf of ESPN Immune Mediated Renal Disorders WG members
 
Introduction:

 Crescentic glomerulonephritis can be caused by different pathogenic mechanisms with severe glomerular damage. Different approaches can impact the success of the management of crescentic glomerulonephritis. Our objective is to obtain data on the etiology, diagnosis and management of crescentic glomerulonephritis across Europe. 

Material and methods:

 A web-based questionnaire was prepared by ESPN Working Group for Immune Mediated Renal Disorders and questionnaire results were evaluated 

Results:

 One hundred active members of ESPN from 19 countries participated in the study. 91% of them are working in a university hospital and they have required facilities for the diagnosis of crescentic glomerulonephritis. Crescentic glomerulonephritis etiology is related with immune-complex mediated in 89.61% of the patients, pauci-immune mediated in 83.12 of them, anti-GBM nephritis  in 58.44% of them and 20.78% of all patients are related to other etiologies. %97 of them takes advantage of pathological findings for the diagnosis and they prefer pathological findings to clinical and other laboratory findings. Glucocorticoids (100%) and cyclophosphamide (75.31%) are the first choice of treatment for induction therapy. Plasma exchange (66.67%), mycophenolate mofetil (29.63%), rituximab (27.16%) and azathioprine (1.23%) are other treatment modalities. Mycophenolate mofetil is mostly used medication (85.19%) for maintenance therapy followed by glucocorticoids (83.95%), azatioprine (41.98%), rituximab (22.22%).

Conclusions:

 Although approaches for diagnosis and management of crescentic glomerulonephritis are similar across Europe, a consensus will increase the success of the management of the crescentic glomerulonephritis.